PolymarketVerifica disponibilitàSenza KYCDati di risoluzione verificatiBen calibratoAvviso sulla qualità dei datiNessuna quotazione live
Dati al 5 ott 2026, 22:11 UTC · criterio pm-quality-4
Probabilità implicita attuale
June 30, 83%
June 30, 83%Qualità del mercato
≤49 / 100
Bassa qualitàVolume 24h
—
Liquidità
7K €
Liquidità mediaBid / Ask
82.0% / 83.0%
Spread
1.0 pt
Spread strettoCommenti
0
Dati di mercato
Aggiornato 5 minuti fa
19 ago 26, 18:47 UTC1 lug 27, 03:59 UTC
Trend
Condizioni della piattaforma
Fonte: Polymarket
Queste condizioni sono informative; il trading simulato di CoinRithm segue regole proprie.
- Ordine minimo (quote):
- 5
- Incremento di prezzo:
- 1 punti percentuali
- Commissioni:
- Sì
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRegole
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.